We aimed to identify the predictors of angiographically visible distal embolization (AVDE) during primary percutaneous coronary intervention (p-PCI) as well as to assess its impact on short-and long-term clinical outcomes in patients with acute ST-segment elevation myocardial infarction (STEMI).
D
espite the high success rates in the achievement of infarct-related artery (IRA) patency, primary percutaneous coronary intervention (p-PCI) fails to maintain microvascular reperfusion in a significant proportion of patients with acute ST-segment elevation myocardial infarction (STEMI). [1] This phenomenon of no-reflow has been shown to be associated with adverse clinical outcomes. [2] The multifactorial pathogenesis of no-reflow phenomenon has been defined by four main mechanisms: ischemic injury, reperfusion injury, individual susceptibility to injury, and distal atherothrombotic embolization. [1] Emboli of varying sizes originating from epicardial coronary thrombosis and atherosclerotic plaque are evident in most cases of acute myocardial infarction (MI). Although the rate of microembolization has been reported to be as high as 79%, [3] angiographically visible distal embolization (AVDE) is present in only 15-19% of the cases. [4, 5] Recently, thrombectomy catheters and distal protection devices have been developed in order to prevent DE. However, large multicenter randomized trials have reported conflicting data about the benefit of these devices in terms of microvascular reperfusion and prognosis. [6] [7] [8] This fact may have been related with the enrollment of patients regardless of clinical and angiographic characteristics. No-reflow has a multifactorial pathogenesis, and the predominant mechanism may vary in each patient. Thus, individualization of prevention and treatment strategies may be important. Therefore, identifying the predictors of different pathogenetic mechanisms seems to be important.
We aimed to identify the predictors of AVDE during p-PCI in patients with acute STEMI, as well as to assess its impact on tissue level reperfusion and clinical outcomes.
PATIENTS AND METHODS

Study population
We retrospectively studied 2007 patients with acute STEMI who underwent p-PCI from January 2006 to December 2008. The inclusion criteria were: 1-admission within the first 12 hours of the onset of typical ischemic chest pain, and [2] ST elevation of at least 1 mm in two or more contiguous leads (2 mm for leads V1 to V3) or new-onset left bundle branch block. Patients were divided into two groups according to the presence (AVDE, n=135) or a b s e n c e ( N o -AV D E , n=1872) of AVDE.
The study was approved by our local ethics c o m m i t t e e , and all patients gave written informed consent for PCI.
Coronary angiography and percutaneous coronary intervention
All patients received a 300 mg chewable aspirin and a 600 mg loading dose of clopidogrel on admission, and 70 U/kg intravenous standard heparin before the procedure. The use of glycoprotein IIb/IIIa receptor antagonist (tirofiban), with 10 µg/kg bolus and 0.15 µg/kg/min intravenous infusion, was left to the primary operator's discretion. Nitroglycerin (intravenously or orally) was given to patients who had no contraindication. Coronary angiographies and interventions were performed by experienced operators with standard methods through femoral access. Conventional or direct stenting was performed according to the lesion characteristics. Preprocedural lesion characteristics, thrombus burden, retrograde filling, initial and postprocedural thrombolysis in myocardial infarction (TIMI) flow grades, and myocardial blush grade (MBG) were evaluated in at least two non-foreshortened angiographic views at the end-diastole [9] by two cardiologists who were unaware of the study groups. Quantitative analyses such as reference vessel diameter (RVD) and diameter stenosis (DS) were performed as well (QCA, Siemens Medical Systems, Germany). After the intervention, all patients were given 1 mg/ kg of subcutaneous enoxaparin twice daily until discharge (dosages were adjusted according to age and renal function), 150 mg/day of acetyl salicylic acid, and 75 mg/day of clopidogrel.
Data collection and long-term follow-up
All clinical and demographic properties of the patients were recorded from hospital files and computer records. On admission, peripheral venous blood samples for hemogram, urea, creatinine, glucose, creatine kinase-MB isoform (CK-MB), troponin I, and C-re- active protein (CRP) were obtained. Blood samples were repeated for cardiac enzymes every 6 hours until peak levels were reached, and were repeated daily thereafter. Hemographic parameters and urea and creatinine levels were also evaluated every day. STsegment resolution (STR) was calculated as the ratio of the sum of ST-segment elevation on admission minus the sum of ST-segment elevation 60 minutes after p-PCI divided by the sum of ST-segment elevation on admission. STR >70% was defined as complete resolution. [10] Postprocedural left ventricular ejection fraction (LVEF) was calculated using biplane modified Simpson method by transthoracic echocardiography (Vivid 3-5, GE, Horten, Norway). The long-term follow-up data (median: 42 months) of the patients were obtained from follow-up visits or in-hospital clinical records of the re-hospitalized patients. In addition, all the patients were contacted by telephone. In order to learn whether the patients who could not be reached were still alive or not, we checked the records of the Statistical Institute and Birth Registration Office. Nevertheless, 56 (2.8%) patients who could not be reached because of insufficient data were excluded from the long-term follow-up.
Definitions
Multivessel disease was described as the presence of a >50% diameter stenosis in two or more major epicardial arteries. Angiographic thrombus burden was evaluated according to the TIMI thrombus scoring, and TIMI score ≥4 was noted as high-grade thrombus burden. [11] Preprocedural collateral flow was evaluated according to the Rentrop classification, and grade 2/3 was noted as well-developed collaterals. [12] AVDE was defined as persistent distal filling defect with an abrupt "cut-off" in one or more peripheral coronary branches of the IRA as a result of dislodgement of a proximal thrombus spontaneously or following wiring and balloon dilatation. Coronary occlusion patterns were evaluated according to previous definitions. [13] Re-infarction was defined as the recurrence of typical clinical symptoms and new electrocardiogram (ECG) changes with a new elevation of the CK-MB fraction levels >2 times the upper limit of normal or any rise by ≥50% above a previously elevated level.
Statistical analysis Continuous variables are expressed as mean±standard deviation or median (interquartile range [IQR]
). Categorical variables are expressed as numbers and percentages. Group means for continuous variables were compared with the use of independent samples t-test or Mann-Whitney U-test, as appropriate. Categorical variables were compared with the use of chi-square or Fisher's exact test. Multivariate logistic regression analysis was applied to identify the independent predictors of AVDE. All variables showing a significance value <0.05 on univariate analysis (age, previous PCI, Killip class >1, baseline creatinine, glucose, leukocyte, neutrophil and monocyte counts, culprit LAD, culprit RCA, TIMI thrombus score, proximal lesion location, occlusion pattern, initial TIMI flow grade, lesion length, RVD, balloon inflation pressure, repeated balloon dilatation, and direct stenting) were included in the model. Receiver operating characteristic (ROC) curve analysis was performed in order to detect optimal cut-off values of lesion length and RVD for predicting AVDE. Survival curves were calculated using the Kaplan-Meier method, with the significance evaluated using the log-rank tests. without AVDE (p<0.001 for all, Figure 1 ). Other angiographic characteristics are shown in (Table 3) . ROC analysis showed an area under the curve (AUC) of 0.68 for lesion length and AVDE. Lesion length >15 mm showed a sensitivity of 67.4% and a specificity of 71.6% for predicting AVDE (95% CI 0.63-0.73, p<0.001). In ROC analysis, AUC for RVD and AVDE was 0.77 and RVD >3.5 mm showed a sensitivity of 70.4% and a specificity of 76.1% for predicting AVDE (95% CI 0.72-0.81, p<0.001) (Figure 2 ).
In-hospital (8.1% vs. 3.8%, p=0.014) and onemonth (10.8% vs. 4.9%, p=0.004) all-cause mortality rates were higher in patients with AVDE than in patients without AVDE. At the long-term followup (median: 42 months, IQR 37-53), both all-cause (21.5% vs. 10.4%, p<0.001) and cardiac mortality rates (18.4% vs. 8.0%, p<0.001) were higher in patients with AVDE. However, there was no significant difference between the two groups with respect to non-cardiac mortality. In-hospital reinfarction rates of the groups were not different. However, reinfarction rates at one-month (5.8% vs. 2.3%, p=0.017) and long-term follow-up (12.4% vs. 7.1%, p=0.03) were higher in patients with AVDE (Table 4) . Survival curves of the two groups were significantly different (log-rank p=0.002, Figure 3) . 
DISCUSSION
This retrospective study demonstrated that AVDE had an incidence of 6.7% after p-PCI in patients with STEMI. Age, treatment of RCA, recurrent balloon dilatation, cut-off occlusion pattern, RVD >3.5 mm, and lesion length >15 mm were all independent predictors of DE. The presence of DE was associated with worse TIMI flow and MBG, less STR, and accordingly lower postprocedural LVEF. In-hospital, one-month and long-term mortality rates were higher in patients with DE. Although the reinfarction rates were higher at both short-and long-term follow-up in patients with DE, revascularization rates were not different from those without DE.
In a significant proportion of patients with STEMI, successful restoration of epicardial coronary artery patency does not lead to adequate reperfusion at the microvascular level. This phenomenon is called noreflow or microvascular obstruction (MVO). DE of thrombi and atherosclerotic debris is one of the main pathogenetic mechanisms of no-reflow. Although microembolization is present in the vast majority of patients, [3] AVDE is evident in a smaller proportion of patients. Henriques et al. previously reported the rate of AVDE as 15%. [5] However, the rate has ranged between 2-8% in later trials. [4, 6, 14] The prognostic significance of the presence and the extent of MVO has been well documented by previous studies.
[ [15] [16] [17] In patients with AVDE, impairment in microvascular flow seems to be more prominent. In a study by Fokkema et al., the rates of MBG 3 and complete STR in patients with AVDE were 3.6% and 22%, respectively. In our study, the rates of MBG 3 and complete STR were 10.9% and 30.5%, respectively.
Thus, it is logical to expect that prevention of AVDE should be associated with lower enzymatic infarct size, less remodeling and better prognosis. However, early randomized trials of thrombectomy catheters and distal embolic protection devices have demonstrated neutral or even negative impacts on reduction of infarct size or improvement in prognosis. [7, 8] In contrast, the REMEDIA, DEAR-MI and TAPAS trials demonstrated that thrombectomy improved microvascular perfusion. [4, [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] A meta-analysis by Burzotta et al. [19] analyzing trials of different thrombectomy devices showed that thrombectomy improved survival in patients treated with glycoprotein IIb/IIIa inhibitors. This discrepancy may be related with the enrollment of patients regardless of their angiographic and clinical characteristics.
Identification of predictors of AVDE might be important for the selection of patients that would benefit more from these adjunctive devices. We found that age, treatment of RCA, recurrent balloon dilatation, cut-off occlusion pattern, RVD >3.5 mm, and lesion length >15 mm were all independent predictors of AVDE. TIMI thrombus score was not associated with AVDE. However, parameters defined by Yip et al., [13] such as cut-off occlusion pattern and large IRA diameter, were found to be independent predictors of AVDE. The association of RCA with AVDE was previously explained by its structure with only a few side branches, leading to stasis and more thrombus formation during occlusion. [20] As the emboli are composed of not only thrombus but also atherosclerotic debris, larger IRA diameter may result in increased plaque burden, leading to increased incidence of AVDE. [21] Trauma caused by recurrent balloon dilatation may lead to embolization of both thrombus and debris.
The benefit of protection against AVDE may vary according to not only the thrombus burden, plaque volume and the device used, but also the contribution of embolization in the pathogenesis of no-reflow in each patient. [22] The predominant pathogenetic mechanism of no-reflow may vary in each individual. Napodano et al. [21] demonstrated that while the occurrence of AVDE was not time-dependent, its impact on epicardial reflow and tissue level reperfusion was time-dependent. They showed that AVDE had no effect on microvascular damage beyond the first 6 hours (h) after symptom onset. Furthermore, they showed that the enzymatic infarct area and in-hospital mortality was affected by only AVDE within the first 3 h. In our study, AVDE was associated with increased in-hospital, one-month and long-term mortality rates. Thus, this may be related with the short pain-to-balloon time in most of our patients. The incidence of reinfarction was also higher in patients with AVDE, and this may have contributed to the increased mortality. These findings suggest that AVDE is an important mechanism in the development of MVO in STEMI patients treated early with p-PCI and affects not only the short-term, but also the longterm clinical outcomes in these patients.
Some limitations of our study should be taken into consideration. First, this study has a single-center and retrospective design. In order to prevent bias, the inhospital and long-term data were collected by different investigators. Second, the incidence of DE may have been underestimated because we evaluated only the angiographically visible macro-emboli. Finally, we measured enzymatic infarct size by peak troponin I, and evaluated microvascular perfusion by STR and MBG. Future prospective studies using optical coherence tomography for evaluating intraluminal thrombi and magnetic resonance imaging for detecting MVO and infarct size would be more valuable. In conclusion, age, treatment of RCA, recurrent balloon dilatation, cut-off occlusion pattern, RVD >3.5 mm, and lesion length >15 mm were all independent predictors of AVDE. These predictors may help in the selection of appropriate patients for use of mechanical adjunctive devices during p-PCI. Angiographically evident DE is associated with poor clinical outcome at both the short-and long-term followup of STEMI patients treated early with p-PCI.
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